Inventiva Competitors

Nuvation Bio (NYSE:NUVB) and Inventiva (NYSE:IVA) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation and institutional ownership.

Profitability

This table compares Nuvation Bio and Inventiva's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Nuvation Bio and Inventiva's top-line revenue, earnings per share and valuation.

Analyst Ratings

This is a summary of current recommendations for Nuvation Bio and Inventiva, as provided by MarketBeat.

Nuvation Bio currently has a consensus target price of $17.40, suggesting a potential upside of 74.00%. Inventiva has a consensus target price of $27.3333, suggesting a potential upside of 89.29%. Given Inventiva's higher possible upside, analysts plainly believe Inventiva is more favorable than Nuvation Bio.

Summary

Nuvation Bio beats Inventiva on 2 of the 3 factors compared between the two stocks.

Inventiva (NYSE:IVA) and ImmunityBio (NASDAQ:IBRX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, institutional ownership, earnings and profitability.

Profitability

This table compares Inventiva and ImmunityBio's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Inventiva and ImmunityBio's gross revenue, earnings per share (EPS) and valuation.

Analyst Recommendations

This is a breakdown of recent ratings for Inventiva and ImmunityBio, as reported by MarketBeat.

Inventiva currently has a consensus price target of $27.3333, suggesting a potential upside of 89.29%. ImmunityBio has a consensus price target of $25.00, suggesting a potential upside of 48.19%. Given Inventiva's higher probable upside, research analysts plainly believe Inventiva is more favorable than ImmunityBio.

Summary

Inventiva beats ImmunityBio on 2 of the 3 factors compared between the two stocks.

Inventiva (NYSE:IVA) and BioAtla (NASDAQ:BCAB) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, institutional ownership, earnings and profitability.

Profitability

This table compares Inventiva and BioAtla's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Inventiva and BioAtla's gross revenue, earnings per share (EPS) and valuation.

Analyst Recommendations

This is a breakdown of recent ratings for Inventiva and BioAtla, as reported by MarketBeat.

Inventiva currently has a consensus price target of $27.3333, suggesting a potential upside of 89.29%. BioAtla has a consensus price target of $58.00, suggesting a potential upside of 22.49%. Given Inventiva's higher probable upside, research analysts plainly believe Inventiva is more favorable than BioAtla.

Inventiva (NYSE:IVA) and Immunocore (NASDAQ:IMCR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, institutional ownership, earnings and profitability.

Profitability

This table compares Inventiva and Immunocore's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Inventiva and Immunocore's gross revenue, earnings per share (EPS) and valuation.

Analyst Recommendations

This is a breakdown of recent ratings for Inventiva and Immunocore, as reported by MarketBeat.

Inventiva currently has a consensus price target of $27.3333, suggesting a potential upside of 89.29%. Immunocore has a consensus price target of $54.3333, suggesting a potential upside of 53.18%. Given Inventiva's higher probable upside, research analysts plainly believe Inventiva is more favorable than Immunocore.

Summary

Inventiva beats Immunocore on 2 of the 3 factors compared between the two stocks.

Inventiva (NYSE:IVA) and Cullinan Oncology (NASDAQ:CGEM) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, institutional ownership, earnings and profitability.

Profitability

This table compares Inventiva and Cullinan Oncology's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Inventiva and Cullinan Oncology's gross revenue, earnings per share (EPS) and valuation.

Analyst Recommendations

This is a breakdown of recent ratings for Inventiva and Cullinan Oncology, as reported by MarketBeat.

Inventiva currently has a consensus price target of $27.3333, suggesting a potential upside of 89.29%. Cullinan Oncology has a consensus price target of $48.25, suggesting a potential upside of 49.38%. Given Inventiva's higher probable upside, research analysts plainly believe Inventiva is more favorable than Cullinan Oncology.

Summary

Inventiva beats Cullinan Oncology on 2 of the 3 factors compared between the two stocks.

Inventiva (NYSE:IVA) and Cricut (NASDAQ:EWTX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, institutional ownership, earnings and profitability.

Profitability

This table compares Inventiva and Cricut's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Inventiva and Cricut's gross revenue, earnings per share (EPS) and valuation.

Analyst Recommendations

This is a breakdown of recent ratings for Inventiva and Cricut, as reported by MarketBeat.

Inventiva currently has a consensus price target of $27.3333, suggesting a potential upside of 89.29%. Given Inventiva's higher probable upside, research analysts plainly believe Inventiva is more favorable than Cricut.

Summary

Inventiva beats Cricut on 2 of the 2 factors compared between the two stocks.